Literature DB >> 2948901

Regulation of autoimmune disease physiological and therapeutic.

I R Cohen.   

Abstract

An important question is how the immune system can control the behavior of autoimmune effector lymphocytes. My colleagues and I have investigated this question in four models. Three models of organ specific autoimmune diseases were studied using the specific autoimmune lines or clones of T lymphocytes functionally involved in the disease process. The fourth model was an anti-idiotypic network triggered spontaneously by autoantibodies. This article reviews the evidence indicating that healthy individuals can carry potentially virulent autoimmune T lymphocytes without symptoms. This carrier state of autoimmunity implies the existence of natural mechanisms of counter-autoimmunity. One natural element appears to be clones of suppressor-inducer T lymphocytes that arise in the course of the autoimmune response. We have discovered that autoimmune effector T lymphocytes can serve as inducers of their own suppression either artificially, by manipulating the T cell membrane, or naturally, by exposing the individual to very low concentrations of some effector T cell clones. Regarding the regulation of autoreactive B lymphocytes, we have observed that spontaneous generation of anti-idiotypic antibodies may have a particular bias for autoantibody idiotypes. Counter-autoimmunity appears to involve recognition of the self-reactive lymphocyte receptors resulting in the activation of suppressor cells. These suppressor cells can prevent disease or cause remission of established disease.

Entities:  

Mesh:

Year:  1986        PMID: 2948901     DOI: 10.1111/j.1600-065x.1986.tb01161.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  34 in total

Review 1.  Immunoregulation: studies of physiological and therapeutic autoreactivity by T cell vaccination.

Authors:  A W Lohse; I R Cohen
Journal:  Springer Semin Immunopathol       Date:  1992

Review 2.  T cell regulation in autoimmune arthritis: possibilities for immunological intervention.

Authors:  W van Eden
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 3.  Immunotoxicology: suppressive and stimulatory effects of drugs and environmental chemicals on the immune system. A discussion.

Authors:  E Gleichmann; I Kimber; I F Purchase
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

Review 4.  The 65-kDa heat-shock protein in the pathogenesis, prevention and therapy of autoimmune arthritis and diabetes mellitus in rats and mice.

Authors:  U Feige; I R Cohen
Journal:  Springer Semin Immunopathol       Date:  1991

Review 5.  Premises for immune interventional therapy in rheumatoid arthritis.

Authors:  I R Mackay; M J Rowley
Journal:  Postgrad Med J       Date:  1988-07       Impact factor: 2.401

6.  Defective T-cell surface antigen expression after mitogen stimulation. An index of lymphocyte dysfunction after controlled murine injury.

Authors:  M A Gadd; J F Hansbrough; D B Hoyt; N Ozkan
Journal:  Ann Surg       Date:  1989-01       Impact factor: 12.969

7.  Breakdown of self-tolerance by intrathymic injection of a T-cell line inducing autoimmune gastritis in mice.

Authors:  A Nishio; T Katakai; M Hosono; M Inaba; M Sakai; M Okuma; S Kasakura; T Masuda
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

8.  Immunological characterization of a human homolog of the 65-kilodalton mycobacterial antigen.

Authors:  A K Dudani; R S Gupta
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

9.  Shifts in the epitopes of myelin basic protein recognized by Lewis rat T cells before, during, and after the induction of experimental autoimmune encephalomyelitis.

Authors:  F Mor; I R Cohen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 10.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.